Royalty Pharma Plc (RPRX)
56.66
-0.50
(-0.87%)
USD |
NASDAQ |
Oct 05, 16:00
56.64
-0.02
(-0.03%)
After-Hours: 20:00
Royalty Pharma Enterprise Value : 36.33B for Oct. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 36.33B |
| October 02, 2026 | 36.56B |
| October 01, 2026 | 36.77B |
| September 30, 2026 | 37.09B |
| September 29, 2026 | 37.03B |
| September 28, 2026 | 37.10B |
| September 25, 2026 | 37.02B |
| September 24, 2026 | 37.06B |
| September 23, 2026 | 36.78B |
| September 22, 2026 | 37.16B |
| September 21, 2026 | 37.13B |
| September 18, 2026 | 37.11B |
| September 17, 2026 | 37.35B |
| September 16, 2026 | 37.14B |
| September 15, 2026 | 37.14B |
| September 14, 2026 | 37.40B |
| September 11, 2026 | 37.20B |
| September 10, 2026 | 37.27B |
| September 09, 2026 | 38.09B |
| September 08, 2026 | 38.09B |
| September 04, 2026 | 39.59B |
| September 03, 2026 | 39.55B |
| September 02, 2026 | 39.21B |
| September 01, 2026 | 38.86B |
| August 31, 2026 | 38.45B |
| Date | Value |
|---|---|
| August 28, 2026 | 38.20B |
| August 27, 2026 | 38.68B |
| August 26, 2026 | 38.62B |
| August 25, 2026 | 38.75B |
| August 24, 2026 | 38.42B |
| August 21, 2026 | 38.41B |
| August 20, 2026 | 38.08B |
| August 19, 2026 | 38.59B |
| August 18, 2026 | 37.68B |
| August 17, 2026 | 37.58B |
| August 14, 2026 | 37.20B |
| August 13, 2026 | 37.18B |
| August 12, 2026 | 37.47B |
| August 11, 2026 | 36.84B |
| August 10, 2026 | 36.92B |
| August 07, 2026 | 36.38B |
| August 06, 2026 | 36.60B |
| August 05, 2026 | 36.82B |
| August 04, 2026 | 36.70B |
| August 03, 2026 | 36.56B |
| July 31, 2026 | 37.12B |
| July 30, 2026 | 37.39B |
| July 29, 2026 | 37.46B |
| July 28, 2026 | 37.81B |
| July 27, 2026 | 37.26B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 511.80B |
| Johnson & Johnson | 637.39B |
| Merck & Co., Inc. | 391.25B |
| Viatris, Inc. | 32.57B |
| ANI Pharmaceuticals, Inc. | 1.902B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 81.49M |
| Revenue (Quarterly) | 674.14M |
| Total Expenses (Quarterly) | 656.26M |
| EPS Diluted (Quarterly) | 0.04 |
| Gross Profit Margin (Quarterly) | 99.81% |
| Profit Margin (Quarterly) | 12.09% |
| Earnings Yield | 3.32% |
| Operating Earnings Yield | 5.31% |
| Normalized Earnings Yield | 3.117 |